- 1 Performance of microbiological tests for tuberculosis diagnostic according to the type
- 2 of respiratory specimen: a 10-year retrospective study
- 4 Short title:

3

6 7

10 11 12

20

22

26

- 5 Diagnostic tests for pulmonary tuberculosis
 - **Authors**
- 8 Marc-Olivier Boldi¹, Justin Denis-Lessard¹, Rina Neziri¹, René Brouillet², Christophe von-
- Garnier³, Valérie Chavez¹, Jesica Mazza-Stalder³, Katia Jaton², Gilbert Greub^{2,4}, Onya Opota² 9

Affiliations

- 13 (1) Faculty of Business and Economics, University of Lausanne, Switzerland.
- 14 (2) Institute of Microbiology, Lausanne University and University Hospital of Lausanne,
- Lausanne, Switzerland. 15
- (3) Pulmonary Division, Lausanne University Hospital, University of Lausanne, Lausanne, 16
- 17 Switzerland.
- 18 (4) Infectious Diseases Service, Lausanne University and University Hospital of Lausanne,
- 19 Lausanne, Switzerland.
- 21 Corresponding author: Onya Opota, onya.opota@chuv.ch
- 23 Key words:
- 24 Tuberculosis, microscopy, PCR, mycobacterial culture, bronchoalveolar lavage, bronchial
- 25 aspirate, sputum, induced-sputum, acid-fast bacilli (AFB).

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

Abstract

27

28

37

44

55

60

61

62 63

64

65

66

67

Background:

- The microbial diagnosis of tuberculosis (TB) remains challenging and relies on multiple microbiological tests performed on different clinical specimens. Polymerase chain reactions (PCRs), introduced in the last decades has had a significant impact on the diagnosis of TB. However, questions remain about the use of PCRs in combination with conventional tests for
- TB, namely microscopy and culture. We aimed to determine the performance of microscopy,
- 34 culture and PCR for the diagnosis of pulmonary tuberculosis according to the type of clinical
- 35 specimen in order to improve the diagnostic yield and to avoid unnecessary, time and labor-
- 36 intensive tests.

Methods:

- 38 We conducted a retrospective study (2008-2018) on analysis (34'429 specimens, 14'358
- patients) performed in our diagnostic laboratory located in the Lausanne University Hospital to
- 40 compare the performance of microbiological tests on sputum, induced sputum, bronchial
- 41 aspirate and bronchoalveolar lavage (BAL). We analysed the performance using a classical
- 42 "per specimen" approach and a "per patient" approach for paired specimens collected from the
- 43 same patient.

Results:

- The overall sensitivities of microscopy, PCR and culture were 0.523 (0.489, 0.557), 0.798
- 46 (0.755, 0.836) and 0.988 (0.978, 0.994) and the specificity were 0.994 (0.993, 0.995), 1 (0.999,
- 47 1) and 1 (1, 1). Microscopy displayed no significant differences in sensitivity according to the
- 48 type of sample. The sensitivities of PCR for sputum, induced sputum, bronchial aspirate and
- 49 BAL were, 0.821 (0.762, 0.871), 0.643 (0.480, 0.784), 0.837 (0.748, 0.904) and 0.759 (0.624,
- 50 0.865) respectively and the sensitivity of culture were, 0.993 (0.981, 0.998), 0.980 (0.931,
- 51 0.998), 0.965 (0.919, 0.988), and 1 (0.961, 1) respectively. Pairwise comparison of specimens
- 52 collected from the same patient reported a significantly higher sensitivity of PCR on bronchial
- aspirate over BAL (p < 0.001) and sputum (p < 0.05) and a significantly higher sensitivity of
- 54 culture on bronchial aspirate over BAL (p < 0.0001).

Conclusions:

- 56 PCR displayed a higher sensitivity and specificity than microscopy for all respiratory specimens,
- 57 a rational for a smear-independent PCR-based approach to initiate tuberculosis microbial
- 58 diagnostic. The diagnosis yield of bronchial aspirate was higher than BAL. Therefore, PCR
- should be systematically performed also on bronchial aspirates when available.

1. Introduction

With over ten million new cases in 2020 and about 1,5 million deaths, tuberculosis represents a major public health concern [1]. Rapid and reliable diagnosis is important to reduce morbidity and mortality associated with tuberculosis and to control transmission. When tuberculosis is suspected based on clinical symptoms, epidemiological information and radiological findings, microbial confirmation is key to establish the diagnosis. Despite progress during the last decades, the microbiological diagnosis of tuberculosis continues to be a challenge particularly in paucibacillary disease. Historically, the diagnosis of tuberculosis was based on microscopy

and culture. Mycobacterial culture represents the reference method due to a low limit of detection (< 10 organisms for liquid cultures) and because it gives access to the strain for phenotypic antibiotic susceptibility test [1,2]. However, culture is challenging due to the slow growth of *M. tuberculosis* and because it requires biosafety level three (BSL3) laboratories [3.4]. Microscopy based on the visualization of acid-fast bacilli provides rapid results (<30 minutes) but has a limited sensitivity and specificity (limit of detection between 10³ and 10⁴ bacilli per ml) [5]. In order to increase their sensitivity, these tests may need to be repeated over several clinical specimen [1,6,7].

More recently, molecular diagnosis, in particular polymerase chain reaction (PCR) have improved the diagnosis of tuberculosis with a limit of detection between 10 and 10³ colony forming units per ml and a turnaround time between two to six hours [2,6,8,9]. PCR was initially available in laboratories specialized in molecular diagnostics, through methods developed inhouse assays [10,11]. Commercial all-inclusive systems, such as the GeneXpert system, now allow a greater number of laboratories to perform this analysis independently of a specialized infrastructure [6,8,9,12]. The GeneXpert system not only improved the initial diagnostic of tuberculosis but can be used to assess patient's infectious potential, on the basis of the semiquantitative results [2,5,8]. In addition, rapid molecular test also shortens airborne isolation for hospitalized patients with presumptive tuberculosis [13]

More than 70% of the tuberculosis infections are pulmonary tuberculosis, for which sputum is the usual specimen collected in adults and older children who are able to collaborate. Other respiratory specimens can be considered when patients are not able to provide sputum or to increase microbial diagnostic yield [10]. This includes induced sputum, obtained by nebulization of sterile hypertonic saline (3% or 7% saline solution inhaled) followed by coughing and expectoration of airway secretions, bronchial aspirate, and bronchoalveolar lavages [14,15].

In this study, we aimed to assess the performance of the different tests for the microbial diagnostic of tuberculosis according to the type of clinical specimen. Providing robust updated data may enable to choose optimal combination of test and specimen to: i) reach the maximum sensitivity, specificity and negative and predicative value, ii) prioritize the tests and specimens in the situation of limited resources or shortage of material and iii) reduce unnecessary costs.

There is no standard method to address the performance of diagnostic tests, particularly for tuberculosis where several microbiological tests on multiple clinical samples are frequently required. We applied data analytics methods that integrate multiple parameters, including, the type of microbiological test, the type of specimens, the sampling period, and the patients. In this study, we performed both a classical "per specimen" method to determine the performance of each diagnostic test and a "per patient" approach comparing paired specimens collected from the same patient.

This study provides data to establish diagnostic stewardship guidelines and diagnostic protocols. These data will help to establish more effective strategies to diagnose pulmonary tuberculosis in order to increase the rate of documentation, to accelerate the diagnosis and avoid unnecessary testing. In addition, it should provide analytical strategies that may also be suitable to study other infectious diseases while keeping associated medical, social and economic costs to a strict minimum.

68 69

70

71

72

73

74

75

76

77

78

79

80

81

82 83

84

85

86

87

88

89

90 91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106 107

108

2. Material and Methods

2.1 Study Design and data

Our laboratory is located in the Lausanne University Hospital (CHUV), a 1'500 beds tertiary-care hospital in a low-tuberculosis-prevalence country (Switzerland), with approximately six new cases per year per 100,000 population (Federal Office of Public Health; http://www.bag.admin.ch/). The data included microbiology analyses for patients with suspected mycobacterial infection from 2008 to 2018. They were automatically extracted from the Laboratory Information System (MOLIS, CGM).

For all specimens, information regarding the microbial diagnostic of mycobacteria were extracted. This included information regarding microscopy, PCR, cultures, molecular and phenotypic resistance genes together with the type of specimen and the date of collection. Each specimen was given a unique coded number. Similarly, each patient was given a unique coded number. The database was generated to allow analysis by date of sampling and by patients (see Section 2.4). For the microbial diagnostic of the disease, we generated a composite gold

standard including microbiological findings and epidemiological and clinical data (see Section

2.3). The final database included 34'429 specimens corresponding to 14'358 patients, including

2.2 Clinical specimens and mycobacterial diagnostic test

8'587 sputum, 2'257 induced sputum, 8'610 bronchial aspirate and 4'576 BAL.

This study focuses on three microbial diagnostic tests commonly used for the diagnostic of mycobacterial infections, namely (i) microscopy (also named smear microscopy) for the direct detection of acid-fast bacilli (AFB) in clinical specimen, (ii) PCR for the detection of DNA of *M. tuberculosis* complex directly from clinical specimen and (iii) mycobacterial culture. Microscopy consists in acid-fast bacillus staining achieved through a fluorescent auramine-thiazine red staining on a heat-fixed smear as described in [8]. PCR consisted of either an in-house TaqMan PCR targeting the multicopy *M. tuberculosis* IS6110 sequence, named PCR "MYTU" [11] or using the all-inclusive rapid molecular test Xpert MTB/RIF and Xpert MTB/RIF Ultra (herafter named Xpert) (Cepheid, Ca, USA) [6,8,16]. Mycobacterial culture was achieved using mycobacterial growth indicator tube (MGIT) that consists in culture tubes containing tris 4, 7-diphenyl-1, 10-phenonthroline ruthenium chloride pentahydrate, an oxygen-quenched fluorochrome embedded in silicone at their bottom. Utilization of free oxygen for growing bacteria alleviates the fluorochrome quenching, resulting in fluorescence within the tube that can be visualized under UV light, as explained in a previous publication [8].

All the microbial analyses were performed on the same sample after splitting it for AFB staining, Xpert analysis and mycobacterial culture [8]. Sputum, induced sputum, bronchial aspirate and

All the microbial analyses were performed on the same sample after splitting it for AFB staining, Xpert analysis and mycobacterial culture [8]. Sputum, induced sputum, bronchial aspirate and bronchoalveolar lavage were processed as previously described [8]. In particular, samples with a volume exceeding 3 mL were concentrated by centrifugation (30 minutes, 3000 g). In addition, to increase the homogeneity of the sample before smear preparation, purulent sputum or bronchial aspirates were solubilized with the mucolytic agent N-acetyl-L-cysteine (2% v/v pH 6.8) [8].

2.3 Composite gold standard

 Mycobacterial culture is the gold standard for the diagnosis of *M. tuberculosis* because of its lowest limit of detection (LOD < 10 organisms). However, it can be impaired by situation that affect mycobacterial growth such as the introduction of an antibiotic treatment before sampling [2]. We therefore used a composite gold standard based on microbiological results and clinical data. Discrepant results in the diagnostic of active tuberculosis, especially specimen with positive MTBC PCR and negative culture for *M. tuberculosis* complex, were manually cured based on clinical and epidemiological data found in medical records. Specimens for which the culture was contaminated by bacteria of the flora were excluded. Specimens with culture positive with nontuberculous mycobacteria qualified as "MOTT" (Mycobacteria other than tuberculosis) were considered negative for *M. tuberculosis*. This resulted in the "Gold Standard" (GS) reference.

2.4 Performance of the test depending on the clinical specimens

We used two different approaches to determine the performance of microbiological tests depending on the clinical specimens. We first used a common "per specimen" approach to determine the global performance of microscopy, PCR, and culture according to the four types of specimens and independently of the patient using the GS as reference. Then, in order to provide more robust data we performed a "per patient" approach. It consists in pairwise comparison for specimens collected the same day or during a window of 72 hours for the same patient; indeed, samples from the same patient might not be collected the same day. For each patient, the first sample was paired to the following sample if it was of a different type and within a 72-hour window. All the combinations of the four types of specimens were analyzed using this pairwise approach i) to measure the dependence between each pair of types of specimens and ii) to calculate the performance of one sample type to predict a positive of any of the two sample types.

2.5 Statistics

The performance measures consist in accuracy, sensitivity, specificity, positive and negative predictive values. They were computed using GS as reference. Their respective 95% confidence intervals were computed using the Clopper–Pearson method. The comparisons of proportions were assessed with a two-sided proportion test with Yates' continuity correction. The dependence between pairs of types of specimens for the "per patient" approach is measured by the Cohen's Kappa.

2.6 Ethics committee approval

This study was approved by the relevant ethics committee, the *Commission Cantonale* d'Éthique de la Recherche sur l'Être Humain (CER-2020-00136).

3. Results

3.1 Global performance of microscopy, PCR and culture for the diagnostic of pulmonary tuberculosis.

- 194 We first determined the global performance of microscopy. The sensitivity, 0.523 (0.489 -
- 195 0.557) and the PPV, 0.767 (0.730, 0.800) of microscopy were limited. The specificity, 0.994
- 196 (0.993, 0.995), and the NPV 0.982 (0.981, 0.984) were high but must be interpreted according
- to the low prevalence of microscopy positive specimen 0.036 (0.034, 0.038) (Table 1 and Table 197
- 198 S1).

213

214

215

216

219

191

192

193

- Regarding PCR, we first estimated the individual performance of the in-house TaqMan PCR 199
- 200 and the rapid molecular test Xpert. The sensitivity of the in-house TagMan PCR, 0.799 (0.743,
- 0.848) and Xpert 0.812 (0.760, 0.858) were not significantly different (Table S2 and Table S3). 201
- 202 The specificity for both the in-house TagMan PCR >0.999 (0.999, 1) and Xpert 0.999 (0.997,
- 203 1) were both very high. The NPV were also high but probably increased by the low prevalence
- 204 of PCR positive specimen (Table S7). Because the two PCR tests displayed similar
- 205 performance, we considered them as equal for the rest of the study and grouped them as
- 206 "PCR". The global performance of PCR were: sensitivity 0.798 (0.755, 0.836), specificity 1
- 207 (0.999, 1), PPV 0.997 (0.983, 1) and NPV 0.988 (0.985, 0.990) (Table 2 and S2).
- The culture displayed the highest performance for the diagnostic of tuberculosis using the GS 208
- 209 reference with a sensitivity of 0.988 (0.978, 0.994) and a specificity of 1 (1, 1) (Table 3 and
- 210 Table S3). In summary when considering all the clinical specimen, microscopy displays limited
- 211 sensitivity, PCR displays a higher sensitivity than microscopy and an excellent specificity and
- 212 culture displayed the highest sensitivity and specificity.

3.3 Performance of microbiological tests according to the type of specimen using a "per sample" approach or using "per patient" pairwise comparisons.

217 We next measured the dependence between the specimens using the "per patient" approach

and the Cohen's kappa. Though the Cohen's kappa is itself difficult to interpret and the 218

confidence intervals shown in the table were not corrected for multiple comparisons, a large

- 220 value of kappa means that the two sample bring the same information to some extent and thus
- 221 provides little "complementary" information and are so-called "supllementary", i.e not really
- 222 needed. Conversely, a kappa close to zero means that the two sample are "complementary".
- 223 The results are shown in Table S8, S9, S10 and S11. The data suggested that for each
- 224 technique, microscopy, PCR, and culture, most samples are supplementary (i.e. not all
- 225 needed), except i) for microscopy, induced sputum versus bronchial aspirate and BAL, ii) for
- PCR, sputum versus induced sputum and iii) for the culture, induced sputum versus BAL. 226
- 227 Because of their low robustness, we do not want to over interpret these results by concluding
- 228 that the so-called "supplementary" tests don't need to be performed, but this question has to
- 229 be tackled in additional work since it is however to our knowledge the first study showing such
- 230 high dependence & redundancy of the various tests.

3.4 Performance of microscopy according to the type of respiratory specimen.

Using the classical "per specimen" approach-the sensitivities of microscopy for all specimen. sputum, induced sputum, bronchial aspirate and BAL were 0.523 (0.489, 0.557), 0.605 (0.562, 0.647), 0.362 (0.265, 0.467), 0.362 (0.283, 0.447) and 0.462 (0.356, 0.569) respectively. The sensitivity of sputum was higher than induced sputum (p-value < 0.0001) and bronchial aspirate (p-value < 0.0001) (Table 4 and S4). However, using the "per patient" comparison approach, for paired specimens collected within a window of 72h for the same patient, no significant difference was observed for the various specimens (Table 4,S4 and S9). Altogether, these data suggested a limited benefit of microscopy for tuberculosis microbial diagnosis in a low prevalence setting.

3.5 Performance of PCR according to the type of respiratory specimen.

Using the classical "per specimen" approach-the sensitivities of PCR for all specimen, sputum, induced sputum, bronchial aspirate and BAL were 0.798 (0.755, 0.836), 0.821 (0.762, 0.871), 0.643 (0.480, 0.784), 0.837 (0.748, 0.904) and 0.759 (0.624, 0.865) respectively. Using the "per patient" pairwise comparison approach, no significant difference in sensitivity was seen between sputum and induced sputum. Using this approach, we found that the sensitivity of bronchial aspirate, was significantly higher than BAL with respectively 0.974 (0.865, 0.999) and 0.564 (0.396, 0.722) (p. value 0.0003). The sensitivity of bronchial aspirate was also higher than sputum with respectively 1 (0.753, 1) versus 0.385 (0.139, 0.684) (p-value = 0.017) (Table 5,S5 and S10).

These data suggest, no significant difference in the sensitivity of PCR between sputum and induced sputum when the patient can produce spontaneous sputum. In contrast, bronchial aspirate displays higher sensitivity than sputum and BAL. PCR displayed a high specificity for all the respiratory specimens.

3.6 Performance of culture according to the type of respiratory specimen.

Using the classical "per specimen" approach, the sensitivity of culture when considering all respiratory specimen was 0.988 (0.978, 0.994). The sensitivities of culture for sputum, induced sputum, bronchial aspirate and BAL were 0.993 (0.981, 0.998), 0.980 (0.931, 0.998), 0.965 (0.919, 0.988), and 1 (0.961, 1).

Using the "per patient" comparison of paired specimens, no significant difference in sensitivity 267 268 was seen between the different respiratory specimens expect a superiority of bronchial aspirate 269 over BAL, 0.970 (0.914, 0.994) versus 0.636 (0.538, 0.731) (p. value < 0.0001) (Table 6,S6 and S11).

270

231 232

233 234

235

236

237

238

239

240

241

242

243 244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

4. Discussion

271

272

273

274

275

276277278

279280

281282

283284

285286

287 288

289 290

291

292

293

294

295

296

297

298

299

300

301

302

303 304

305

306

307

308 309

310

311

The microbial diagnosis of tuberculosis is based on a combination of different microbiological tests that can be performed on different types of clinical samples. We aimed to identify the most efficient tests and specimen in order to guarantee an ideal sensitivity and specificity and to limit the use of unnecessary tests.

Smear independent diagnostic of tuberculosis

Our results confirm a limited sensitivity of smear microscopy (0.523). The specificity (0.994) remains high, probably because of the extremely low prevalence (0.036) of positive microscopy. Our data suggest a higher sensitivity of microscopy on sputum over the three other samples. This is probably a bias because patients for whom the microbiological diagnosis is not made on spontaneous sputum and who therefore need induced sputum or bronchial aspiration and BAL are patients with paucibacillary infections as previously reported by Cadena et al [17]. Using a pairwise comparison method to avoid the patient effect, we do not see any significant difference in sensitivity of microscopy between the various clinical specimens. With a time to result lower than 30 minutes, microscopy remains virtually the fastest diagnostic test. However, its sensitivity and specificity is limited and it requires a lot of work by specialized personnel and the performance of this test may vary depending on the experience of the examiner [8,18]. In a region with a low prevalence of tuberculosis, the question arises of the usefulness of this test. In 2016, we introduced in our laboratory a smearindependent algorithm for the diagnostic of tuberculosis [8]. For all the suspicion of tuberculosis the microbial diagnosis is initiated by PCR; microscopy were not achieved anymore in emergency but grouped once per day. In case of suspected tuberculosis, we initiated microbial diagnostic by the rapid molecular test Xpert MTB/RIF further replaced by Xpert MTB/RIF Ultra which is used both to detect M. tuberculosis DNA and to address patient infectiousness based on the semi-quantitative result; microscopic analysis was still performed after treatment start, in particular to quide contact tracing and des-isolation decisions [5,8,19]. Another study on the diagnosis of NTM infection also suggested a limited added-value of microscopy when 16S broad range PCR for the detection of NTM is available [18]. Our data suggested that microscopy might be useful only for patients with a high pre-test probability of NTM infections, such as immunocompromised patients or patients with clinical and radiological suspicion of having NTM lung disease. In February 2020, we and other diagnostic laboratory experienced an important staff limitation triggered by the SARS-CoV-2 pandemics. Indeed, during the first wave of the SARS-CoV-2 pandemic, the biomedical technicians were reassigned for the management of the SARS-CoV-2 RT-PCR tests. In this context, we had to rapidly identify all the unnecessary analysis among which was smear microscopy. As an immediate response, we therefore push forward, in February 2020, the smear independent algorithm for the diagnostic of mycobacterial infection. Since then, microscopy for the detection of acid-fast bacilli is achieved only on specific request from

clinicians or for patients with a confirmed diagnostic of tuberculosis; indeed, microscopy can be useful for treatment follow-up because PCR can remain positive for a long period in patient's respiratory specimens even when a treatment is well conducted and for contact tracing investigations. Microscopy in addition to pan-mycobacterial PCR can also be requested when there is a high pre-test probability of NTM infection [18].

Towards less cultures?

312

313

314

315 316

317

318 319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344 345

346

347

348

349

350

351

352

353

PCR has improved the diagnostic of tuberculosis with a lower limit of detection than microscopy and an increased specificity for PCR targeting specific M. tuberculosis DNA sequences such as the IS6110. Culture, the oldest microbiological test for tuberculosis, remains the reference method with the lowest limit of detection [2,3]. The performance of mycobacterial culture, sensitivity (98.8%) and specificity (100%), was calculated using a composite gold standard including all the microbiological tests as well as clinical data. We reported few patients with positive PCR but negative culture. It will therefore be difficult to do without culture. Further optimization strategies could be implemented by selecting the most performant tests on the most efficient clinical samples regarding pulmonary tuberculosis. Thus, we could consider only a combination of (i) samples for PCR-based diagnosis to have short time to results coupled to (ii) a selection of samples to perform the culture warranted to obtain strains for testing susceptibility towards anti-mycobacterial agents and also to guarantee an optimal sensitivity (with delayed results).

When pulmonary tuberculosis is suspected, sputum is the usual specimen that is collected. Regarding microscopy, as indicated above there is no significant difference between the different types of clinical samples. On the other hand, with regard to PCR and culture which are much more sensitive and reliable tests we observed differences between the clinical specimens. When looking at sputum and induced sputum we do not see a significant difference in terms of sensitivity for culture. Several studies reported an increased sensitivity of induced sputum over sputum [20,21]. Using the classical approach or the pairwise comparison in the same patient, we did not observe a significant increase in sensitivity with induced sputum compared to spontaneous sputum. However, the pairwise comparisons suggest an increase in the yield of positivity when performing the two specimens. This conclusion should be confirmed by further studies. BAL and bronchial aspirate are generally coupled. The pairwise comparison demonstrates that in the case of tuberculosis the bronchial aspirate (97% of sensitivity) outcompete BAL (63.6% of sensitivity) suggesting a limited added benefit of the BAL for the diagnosis of tuberculosis. Bronchial aspirate and BAL are invasive, which make prospective studies hardly conceivable. Therefore, this retrospective study, giving access to 3'570 pairwise comparison including these specimen provide important data on their performance. Bronchoscopy is not only useful for tuberculosis diagnosis but also to investigate other infectious or non-infectious disease [22]. For instance, BAL is a very good specimen for the diagnostic of fungal infection such as *Pneumocystis* jirovecii infections or Aspergillus fumigatus infection [23-25]. In view of these results, it is important to consider bronchial aspiration for the diagnosis of tuberculosis, confirming previous studies [26]. A first step would therefore be to always add a search for mycobacteria

on the bronchial aspiration when it is missing in laboratory order. This is what we systematically do in our lab when it is missing. This study provides data for diagnostic stewardship and guidance for physicians and clinical microbiology laboratories. Such data could also help at defining diagnostic strategies in the setting of staff or reagants shortage or to reduce costs. Indeed, even in low prevalence and high-income country, the infrastructure and trained personnel for the diagnostic of tuberculosis is limited [27]. The SARS-CoV-2 pandemics negatively impacted tuberculosis control because of the mobilization of trained staff for other activities or because of the disruption of the supply chain of reagents and compounds for tuberculosis diagnostic and treatments [28,29]. In a context of shortage of reagants or other material for mycobacterial culture like the one we encountered during the COVID-19 pandemic, if a prioritization had to be made, it should be done for the benefit of bronchial aspiration; but this should be decided together with the clinician that can help guiding the decision by providing clinical information for each case.

Limits of the study and perspectives

Molecular diagnostic significantly improved the microbial diagnostic of tuberculosis, in particular the initial diagnostic, but is not yet generalized worldwide [30], mainly for economical reasons. To assess the real economic impact of the management of tuberculosis a costbenefit analysis for the full replacement of microscopy in favor of PCR should be performed since this study demonstrates the effectiveness of PCR over microscopy [31]. Such analysis should incorporate that, in hospital setting, patients might be isolated in specific negative pressure chambers for the duration of the investigation. Such cost-benefit study should also address the risk of nosocomial infection due to delayed diagnostic. Future studies should account for the evolution in practices that may have occurred over the ten years (2008-2018) of the study. It would be worthwhile to relate the data with the evolution of protocols and guidelines that were introduced during the studied period in order not to only add diagnostic tools but also to stop the not useful approaches. This study will also permit to address the dependence between the tests results and many other parameters such as the number of tests, the quality of the clinical specimens and patients characteristics. This will be particularly useful for results interpretation, in particular negative results. Finally, this study is based on a large amount of data over a long period, which was made possible by the fact that all the microbial result are in our LIS since 1995. Although, it may not be the case even in high income country labs, comparison of these results with those obtained at other medical centers should be performed with the view of cross-validating the robustness of the present results.

Conclusions

This study demonstrates that many improvements have been made in the microbiological diagnosis of tuberculosis. There is no doubt about the added value of molecular diagnosis compared to microscopy to initiate the diagnosis of tuberculosis. The limit of a generalization of independent algorithms in microscopy lies in the access to molecular diagnosis. New technologies such as the GeneXpert, which are supposed to solve this problem, are not yet

354

355

356

357

358

359

360

361 362

363

364

365

366

367 368

369

370

371

372

373

374 375

376

377

378

379

380

381

382

383

384 385

386 387

388

389 390

391

392

393

generalized. Regarding tuberculosis, the limit in this case is not technological but again, economical. This study provides data for diagnostic stewardship and for editing guidelines and diagnosis protocols with the purpose to reduce the medical, social and economic costs associated with tuberculosis. Indeed, even in low prevalence and high-income country, the infrastructure and trained personnel for the diagnostic of tuberculosis is limited. Therefore, there is a need to identify the most efficient tests and specimens in order to guarantee the sensitivity and specificity and to limit the number of unnecessary tests. In addition, it provides analytical strategies that may also be suitable for the study of other infectious diseases.

5. Acknowledgements

We are thankful to the Laboratory of Molecular Diagnostic and Mycobacteria of the Institute of Microbiology of the University of Lausanne and Lausanne University Hospital that perform the conventional and molecular analysis for the diagnosis of tuberculosis.

6. References

395

396

397

398

399

400

401

402

403

404

405 406

407

408

409

- 411 1 WHO. Global tuberculosis report 2021. 2021.
- 412 2 van Zyl-Smit RN, Binder A, Meldau R, Mishra H, Semple PL, Theron G, et al. 413 Comparison of quantitative techniques including xpert mtb/rif to evaluate 414 mycobacterial burden. PLOS ONE 2011; 6: e28815.
- 415 3 Palomino JC. Nonconventional and new methods in the diagnosis of tuberculosis: 416 Feasibility and applicability in the field. European Respiratory Journal 2005; 26: 339.
- 417 4 Pfyffer GE, Wittwer F. Incubation time of mycobacterial cultures: How long is long enough to issue a final negative report to the clinician? Journal of clinical microbiology 418 419 2012; **50**: 4188-9.
- 420 5 Opota O, Zakham F, Mazza-Stalder J, Nicod L, Greub G, Jaton K. Added value of xpert mtb/rif ultra for diagnosis of pulmonary tuberculosis in a low-prevalence setting. 421 422 J Clin Microbiol 2019; 57.
- 423 Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid 6 424 molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363: 425 1005-15.
- 426 7 Campelo TA, Cardoso de Sousa PR, Nogueira LL, Frota CC, Zuquim Antas PR. 427 Revisiting the methods for detecting mycobacterium tuberculosis: What has the new 428 millennium brought thus far? Access Microbiol 2021; 3: 000245.
- 429 Opota O, Senn L, Prod'hom G, Mazza-Stalder J, Tissot F, Greub G, et al. Added value 8 430 of molecular assay xpert mtb/rif compared to sputum smear microscopy to assess the 431 risk of tuberculosis transmission in a low-prevalence country. Clin Microbiol Infect 432 2016; **22**: 613-9.
- WHO. Who consolidated guidelines on tuberculosis module 3: Rapid diagnostics for 433 9 434 tuberculosis detection. 2021.
- 435 10 WHO. Who consolidated guidelines on tuberculosis module 2: Screening, systematic 436 screening for tuberculosis disease. 2021.
- Greub G, Sahli R, Brouillet R, Jaton K. Ten years of r&d and full automation in 437 11 438 molecular diagnosis. Future Microbiol 2016; 11: 403-25.
- 439 12 Dorman SE, Schumacher SG, Alland D, Nabeta P, Armstrong DT, King B, et al. Xpert 440 mtb/rif ultra for detection of mycobacterium tuberculosis and rifampicin resistance: A 441 prospective multicentre diagnostic accuracy study. Lancet Infect Dis 2018; 18: 76-84.
- 442 Lippincott CK, Miller MB, Popowitch EB, Hanrahan CF, Van Rie A. Xpert mtb/rif assay 13

- 443 shortens airborne isolation for hospitalized patients with presumptive tuberculosis in 444 the united states. Clin Infect Dis 2014; 59: 186-92.
- 445 14 Weiszhar Z, Horvath I. Induced sputum analysis: Step by step. Breathe 2013; 9: 300.
- 446 15 Schaaf HS, Reuter H. Chapter 22 - practical approaches to ordering diagnostic tests. 447 In: Schaaf HS, Zumla AI, Grange JM, et al., eds. Tuberculosis. Edinburgh: W.B. 448 Saunders 2009; 216-26.
- 449 16 Chakravorty S, Simmons AM, Rowneki M, Parmar H, Cao Y, Ryan J, et al. The new 450 xpert mtb/rif ultra: Improving detection of mycobacterium tuberculosis and resistance 451 to rifampin in an assay suitable for point-of-care testing. MBio 2017; 8.
- 452 17 Cadena AM, Fortune SM, Flynn JL. Heterogeneity in tuberculosis. Nat Rev Immunol 453 2017; **17**: 691-702.
- 18 Andenmatten S, Opota O, Mazza-Stalder J, Nicod L, Greub G, Jaton K. Added 454 455 diagnostic value of 16s rrna gene pan-mycobacterial pcr for nontuberculous 456 mycobacterial infections: A 10-year retrospective study. Eur J Clin Microbiol Infect Dis 457 2019.
- Opota O, Mazza-Stalder J, Greub G, Jaton K. The rapid molecular test xpert mtb/rif 458 19 459 ultra: Towards improved tuberculosis diagnosis and rifampicin resistance detection. 460 Clin Microbiol Infect 2019; **25**: 1370-6.
- 461 20 Biswas S, Das A, Sinha A, Das SK, Bairagya TD. The role of induced sputum in the 462 diagnosis of pulmonary tuberculosis. Lung India: official organ of Indian Chest Society 463 2013; **30**: 199-202.
- 464 21 Seong GM, Lee J, Lee JH, Kim JH, Kim M. Usefulness of sputum induction with 465 hypertonic saline in a real clinical practice for bacteriological yields of active pulmonary 466 tuberculosis. Tuberculosis and respiratory diseases 2014; 76: 163-8.
- 467 22 Sanjeevaiah S, Haranal MY, Buggi S. Role of flexible bronchoscopy in patients with 468 sputum-negative pulmonary tuberculosis. *Indian journal of thoracic and cardiovascular* 469 surgery 2018: **34**: 365-9.
- 470 23 Imbert S, Meyer I, Palous M, Brossas J-Y, Uzunov M, Touafek F, et al. Aspergillus pcr 471 in bronchoalveolar lavage fluid for the diagnosis and prognosis of aspergillosis in 472 patients with hematological and non-hematological conditions. Frontiers in 473 microbiology 2018; **9**: 1877-.
- 474 24 Neofytos D, Garcia-Vidal C, Lamoth F, Lichtenstern C, Perrella A, Vehreschild JJ. 475 Invasive aspergillosis in solid organ transplant patients: Diagnosis, prophylaxis, 476 treatment, and assessment of response. BMC Infect Dis 2021; 21: 296.
- 477 25 Perret T, Kritikos A, Hauser PM, Guiver M, Coste AT, Jaton K, et al. Ability of 478 quantitative pcr to discriminate pneumocystis jirovecii pneumonia from colonization. J 479 Med Microbiol 2020; 69: 705-11.
- 480 26 Maitre T, Ok V, Morel F, Bonnet I, Sougakoff W, Robert J, et al. Sampling strategy for 481 bacteriological diagnosis of intrathoracic tuberculosis. Respir Med Res 2021; 79: 482 100825.
- Cannas A, Paglia MG, Sakhoo DC, Vairo F, Doulla B, Nguhuni B, et al. Strengthening 483 27 484 tuberculosis diagnosis in a low-resource setting: Experience learned in dodoma, 485 tanzania. J Infect Dev Ctries 2013; 7: 676-9.
- 486 28 Armstrong DT, Tacheny EA, Olinger G, Howard R, Lemmon MM, Dasgupta D, et al. 487 Sars-cov-2 supply shortages and tuberculosis diagnostics: Current issues requiring 488 immediate solutions. J Clin Microbiol 2021; 59: e0077821.
- 489 29 Meneguim AC, Rebello L, Das M, Ravi S, Mathur T, Mankar S, et al. Adapting tb 490 services during the covid-19 pandemic in mumbai, india. Int J Tuberc Lung Dis 2020; 491 **24**: 1119-21.
- Mechai F, Cordel H, Guglielmetti L, Aubry A, Jankovic M, Viveiros M, et al. 492 30 493 Management of tuberculosis: Are the practices homogeneous in high-income 494 countries? Front Public Health 2020: 8: 443.
- Dowdy DW, Houben R, Cohen T, Pai M, Cobelens F, Vassall A, et al. Impact and cost-495 31 496 effectiveness of current and future tuberculosis diagnostics: The contribution of 497 modelling. The international journal of tuberculosis and lung disease : the official 498 journal of the International Union against Tuberculosis and Lung Disease 2014; 18:

499 1012-8. 500

501

502

503

504

505 506 507

7. Tables

Table 1. Performance of smear microscopy for the diagnostic of pulmonary tuberculosis according of the type of specimen.

Table 1. Performance of smear microscopy for the diagnostic of pulmonary tuberculosis according of the type of specimen.

	Accuracy	Sensitivity	Specificity	Prevalence	PPV	NPV
All specimens	0.977	0.523	0.994	0.036	0.767	0.982
	(0.975,0.979)	(0.489, 0.557)	(0.993, 0.995)	(0.034, 0.038)	(0.730, 0.800)	(0.981, 0.984)
	23219/23763	447/855	22772/22908	855/23763	447/583	22772/23180
Sputum	0.967	0.605	0.991	0.063	0.825	0.974
	(0.963, 0.971)	(0.562, 0.647)	(0.989, 0.993)	(0.058, 0.068)	(0.783, 0.861)	(0.970, 0.977)
	8132/8409	320/529	7812/7880	529/8409	320/388	7812/8021
Induced sputum	0.966 (0.957, 0.973) 2119/2194	0.362 (0.265, 0.467) 34/94	0.993 (0.988, 0.996) 2085/2100	0.043 (0.035, 0.052) 94/2194	0.694 (0.546, 0.817) 34/49	0.972 (0.964, 0.979) 2085/2194
Bronchial aspirate	0.985	0.362	0.996	0.016	0.573	0.989
	(0.982, 0.988)	(0.283, 0.447)	(0.994, 0.997)	(0.014, 0.019)	(0.464, 0.677)	(0.987, 0.991)
	8463/8591	51/141	8412/8450	141/8591	51/89	8412/8502
BAL	0.986	0.462	0.997	0.020	0.737	0.989
	(0.982, 0.989)	(0.356, 0.569)	(0.994, 0.998)	(0.016, 0.024)	(0.603, 0.845)	(0.986, 0.992)
	4505/4569	42/91	4463/4478	91/4569	42/57	4463/4512

All p.values in supplementary material.

Table 2. Performance of PCR for the diagnostic of pulmonary tuberculosis according to the type of specimen.

Table 2. Performance of PCR for the diagnostic of pulmonary tuberculosis according to the type of specimen.

	Accuracy	Sensitivity	Specificity	Prevalence	PPV	NPV
All specimens	0.988 (0.986, 0.991) 7009/7091		1 (0.999, 1) 6689/6690	0.057 (0.051, 0.062) 401/7091	0.997 (0.983, 1) 320/321	0.988 (0.985, 0.990) 6770/7091
All	0.988	0.585	1 (0.999,	0.028	0.992	0.988
specimens	(0.985,	(0.513,	1)	(0.025,	(0.954, 1)	(0.985,
smear microscopy	0.991)	0.654)	6865/6866	0.032)	117/118	0.990)
negative	6982/7066	117/200		200/7066		6865/6948
All	1 (0.987,	1 (0.983,	1 (0.953,	0.734	1 (0.983,	1 (0.953,
specimens	1)	1)	1)	(0.679,	1)	1)
smear microscopy	286/286	210/210	76/76	0.785)	210/210	76/76
positive				210/286		
Sputum	0.986 (0.980, 0.990) 2525/2562	0.821 (0.762, 0.871) 170/207		0.081 (0.071, 0.092) 207/2562	1 (0.979, 1) 170/170	0.985 (0.979, 0.989) 2355/2562
Induced sputum	0.977 (0.962, 0.987) 636/651	0.643 (0.480, 0.784) 27/42		0.065 (0.047, 0.086) 42/609	1 (0.872, 1) 27/27	0.976 (0.961, 0.986) 609/624
Bronchial aspirate	0.993 (0.988, 0.996) 2256/2273	0.837 (0.748, 0.904) 82/98		0.043 (0.035, 0.052) 98/2273	0.988 (0.935, 1) 82/83	0.993 (0.988, 0.996) 2174/2175
BAL	0.992 (0.986, 0.996) 1592/1605	0.759 (0.624, 0.865) 41/54		0.034 (0.025, 0.044) 54/1605	1 (0.914, 1) 41/41	0.992 (0.986, 0.996) 1551/1564

All p.values in supplementary material

514515

510

511

Table 3: Performance of culture for the diagnostic of pulmonary tuberculosis according to the type of specimen.

Table 3: Performance of culture for the diagnostic of pulmonary tuberculosis according to the type of specimen.

	Accuracy	Sensitivity	Specificity	Prevalence	PPV	NPV
All specimens	>0.999 (0.999, 1) 24019/24030	0.988 (0.978, 0.994) 871/882	1 (1, 1) 23148/23148	0.037 (0.034, 0.039) 882/24030	1 (0.996, 1) 871/871	1 (0.999, 1) 23148/23159
Sputum	>0.999 (0.999, 1) 8583/8587	0.993 (0.981, 0.998) 543/547	1 (1, 1) 8040/8040	0.064 (0.059, 0.069) 547/8587	1 (0.993, 1) 543/543	1 (0.999, 1) 8040/8044
Induced sputum	1 (0.997, 1) 2255/2257	0.980 (0.931, 0.998) 100/102	1 (0.998, 1) 2155/2155	0.045 (0.037, 0.055) 102/2155	1 (0.964, 1) 100/100	1 (0.997, 1) 2155/2157
Bronchial aspirate	>0.999 (0.999, 1) 8605/8610	0.965 (0.919, 0.988) 136/141	1 (1, 1) 8469/8469	0.016 (0.014, 0.019) 141/8610	1 (0.973, 1) 136/136	0.999 (0.999, 1) 8469/8474
BAL	1 (0.999, 1) 4576/4576	1 (0.961, 1) 92/92	1 (0.999, 1) 4484/4484	0.020 (0.016, 0.025) 92/4576	1 (0.961, 1) 92/92	1 (0.999, 1) 4484/4484
All p.values in	n supplementai	y material				

516

517

518

Table 4. Sensitivity of microscopy to predict tuberculosis according to the type of specimen using a 72-hours pairing window in the same patient.

Table 4. Sensitivity of microscopy to predict tuberculosis according to the type of										
specimen using a 72-hours pairing window in the same patient.										
	Sensitivity	NPV								
Sputum versus induced sputum										
Sputum	0.923 (0.640, 0.998) 12/13 ^{n.s}	0.997 (0.986, 1) 390/391 ^{n.s}								
Induced Sputum	0.769 (0.462, 0.950) 10/13 ^{n.s}	0.992 (0.978, 0.998) 390/393 ^{n.s}								
Sputum versus bro	nchial aspirate									
Sputum	0.692 (0.386, 0.909) 9/13 ^{n.s}	0.988 (0.970, 0.997) 337/341 ^{n.s}								
Bronchial aspirate	0.846 (0.546, 0.981) 11/13 ^{n.s}	0.994 (0.979, 0.999) 337/339 ^{n.s}								
Sputum versus BAL	-									
Sputum	1 (0.631, 1) 8/8 ^{n.s}	1 (0.987, 1) 280/280 ^{n.s}								
BAL	0.750 (0.349, 0.968) 6/8 ^{n.s}	0.993 (0.975, 0.999) 280/282 ^{n.s}								
Induced sputum ver	rsus bronchial aspirate									
Induced Sputum	0.500 (0.013, 0.987) 1/2 ^{n.s}	0.982 (0.904, 1) 55/56 ^{n.s}								
Bronchial aspirate	0.500 (0.013, 0.987) 1/2 ^{n.s}	0.982 (0.904, 1) 55/56 ^{n.s}								
Induced sputum ver	rsus BAL									
Induced Sputum	0.333 (0.008, 0.906) 1/3 ^{n.s}	0.962 (0.868, 0.995) 50/52 ^{n.s}								
BAL	0.667 (0.094, 0.992) 2/3 ^{n.s}	0.980 (0.896, 1) 50/51 ^{n.s}								
Bronchial aspirate v	versus BAL									
Bronchial aspirate	0.881 (0.744, 0.960) 37/42 n.s	0.999 (0.997, 1.000) 3528/3533 n.s								
BAL	0.714 (0.554, 0.843) 30/42 n.s	0.997 (0.994, 0.998) 3528/3540 n.s								
All p.values in supple	mentary material									

Table 5. Sensitivity of PCR to predict tuberculosis according to the type of specimen using a 72-hours pairing window in the same patient.

Table 5. Sensitivity of PCR to predict tuberculosis according to the type of specimen									
using a 72-hours pairing window in the same patient.									
	Sensitivity	NPV							
Sputum versus induced sputum									
Sputum	0.667 (0.094, 0.992) 2/3 ^{n.s}	0.992 (0.958, 1) 129/130 ^{n.s}							
Induced sputum	0.667 (0.094, 0.992) 2/3 ^{n.s}	0.992 (0.958, 1) 129/130 ^{n.s}							
Sputum versus bro	nchial aspirate								
Sputum	0.385 (0.139, 0.684) 5/13 *	0.953 (0.909, 0.979) 161/169 ^{n.s}							
Bronchial aspirate	1 (0.753, 1) 13/13 *	1 (0.977, 1) 161/161 ^{n.s}							
Sputum versus BAI	_								
Sputum	0.600 (0.147, 0.947) 3/5 ^{n.s}	0.985 (0.947, 0.998) 132/134 ^{n.s}							
BAL	1 (0.478, 1) 5/5 ^{n.s}	1 (0.478, 1) 132/132 ^{n.s}							
Induced sputum ve	rsus bronchial aspirate								
Induced sputum	0.857 (0.421, 0.996) 6/7 ^{n.s}	0.968 (0.833, 0.999) 30/31 ^{n.s}							
Bronchial aspirate	0.714 (0.290, 0.963) 5/7 ^{n.s}	0.938 (0.792, 0.992) 30/32 ^{n.s}							
Induced sputum ver	rsus BAL								
Induced sputum	1 (0.478, 1) 5/5 ^{n.s}	1 (0.884, 1) 30/30 ^{n.s}							
BAL	0.600 (0.147, 0.947) 3/5 ^{n.s}	0.938 (0.792, 0.992) 30/32 ^{n.s}							
Bronchial aspirate	versus BAL								
Bronchial aspirate	0.974 (0.865, 0.999) 38/39 ***	0.999 (0.995, 1.000) 1142/1143 **							
BAL	0.564 (0.396, 0.722) 22/39 ***	0.985 (0.977, 0.991) 1142/1159 **							
All p.values in supplem	entary material								

Table 6. Sensitivity of culture to predict tuberculosis according to the type of specimen using a 72-hours pairing window within the same patient.

Table 6. Sensitivity of culture to predict tuberculosis according to the type of									
specimen using a 72-hours pairing window within the same patient.									
	Sensitivity	NPV							
Sputum versus induced sputum									
Sputum	0.857 (0.697, 0.952) 30/35 ^{n.s}	0.987 (0.969, 0.996) 368/373 ^{n.s}							
Induced sputum	0.800 (0.631, 0.916) 28/35 ^{n.s}	0.981 (0.962, 0.992) 368/375 n.s							
Sputum versus bro	nchial aspirate								
Sputum	0.613 (0.422, 0.782) 19/31 ^{n.s}	0.964 (0.937, 0.981) 318/330 ^{n.s}							
Bronchial aspirate	0.903 (0.742, 0.980) 28/31 ^{n.s}	0.991 (0.973, 0.998) 318/321 ^{n.s}							
Sputum versus BAL	-								
Sputum	0.895 (0.669, 0.987) 17/19 ^{n.s}	0.993 (0.974, 0.999) 268/270 ^{n.s}							
BAL	0.789 (0.544, 0.939) 15/19 ^{n.s}	0.985 (0.963, 0.996) 268/272 ^{n.s}							
Induced sputum ver	rsus bronchial aspirate								
Induced sputum	0.692 (0.386, 0.909) 9/13 ^{n.s}	0.915 (0.796, 0.976) 43/47 ^{n.s}							
Bronchial aspirate	0.846 (0.546, 0.981) 11/13 ^{n.s}	0.956 (0.849, 0.995) 43/45 ^{n.s}							
Induced sputum ver	rsus BAL								
Induced sputum	0.769 (0.462, 0.950) 10/13 ^{n.s}	0.929 (0.805, 0.985) 39/42 ^{n.s}							
BAL	0.462 (0.192, 0.749) 6/13 ^{n.s}	0.848 (0.711, 0.937) 39/46 ^{n.s}							
Bronchial aspirate									
Bronchial aspirate	0.970 (0.914, 0.994) 96/99***	0.999 (0.997, 1.000) 3471/3474***							
BAL	0.636 (0.538, 0.731) 63/99***	0.990 (0.986, 0.993) 3471/3507***							
All p.values details in s	upplementary material								

8. Supplementary material

545 546

547

Table S1. P-values for Table 1, performance of smear microscopy according of the type of specimen.

MICROSCOP						sig.cod
Υ	Sample1	Sample2	Diff_1m2	p.val	adj.p.val	е
400115401			0.0100481	6.31016E-	6.3102E-	***
ACCURACY	All specimens	Sputum	6	07	06	***
4 0 0 LID 4 0 V	All specimens	In al al	0.0112914	0.00440040	0.0440040	*
ACCURACY	All an animanna	Induced sputum	1	0.00118018	0.0118018	
A C C L ID A C V	All specimens	Bronchial	0.0070024	1.04282E-	0.0001042	***
ACCURACY	All anasimana	aspirate	0.0079934	0.00018404	0.0018404	
ACCURACY	All specimens	BAL	0.0088853	0.00016404	0.0016404	**
ACCURACT	Chutum	DAL	0.0000000	0.82387393	0	
ACCURACY	Sputum	Induced sputum	0.0012432	0.02307393	1	n.s.
ACCURACT	Sputum	Bronchial	4	1.83229E-	1.8323E-	11.5.
ACCUBACY	Sputum		0.0180416	1.03229E-	1.0323E-	***
ACCURACY	Sputum	aspirate	0.0100410	1.73634E-	1.7363E-	
ACCURACY	Sputum	BAL	0.0189335	1.73034E-	09	***
ACCURACT		Bronchial	0.0109333	5.08274E-	5.0827E-	
ACCURACY	Induced sputum	aspirate	0.0192848	09	08	***
ACCURACT	muuceu sputum	aspirate	0.0192040	7.30806E-	7.3081E-	
ACCURACY	Induced sputum	BAL	0.0201767	08	07	***
ACCUITACT	Bronchial	DAL	0.0201707	0.74149137	O1	
ACCURACY	aspirate	BAL	0.0008919	6	1	n.s.
ACCUITACT	aspirate	DAL	0.0000919	0.00338320	0.0338320	11.5.
SENSITIVITY	All specimens	Sputum	0.0821079	6	6.0330320	*
OLNOTTIVITI	All specimens	Opulain	0.1611048	0.00427942	0.0427942	
SENSITIVITY	All specimens	Induced sputum	9	9	9	*
OLIVOITIVITI	All specimens	Bronchial	0.1611048	0.00055236	0.0055236	
SENSITIVITY	7 th opositions	aspirate	9	5	5	**
CLITCHITT	All specimens	aopiiato	0.0612685	0.31654015		
SENSITIVITY	, op co	BAL	6	4	1	n.s.
32.13.11111	Sputum		0.2432128	1.92189E-	0.0001921	
SENSITIVITY	•	Induced sputum	1	05	9	***
	Sputum	Bronchial	0.2432128			
SENSITIVITY	·	aspirate	1	4.0431E-07	4.04E-06	***
	Sputum	·	0.1433764	0.01436764	0.1436764	
SENSITIVITY	·	BAL	7	7	7	n.s.
		Bronchial				
SENSITIVITY	Induced sputum	aspirate	0	1	1	n.s.
			-	0.21854228		
SENSITIVITY	Induced sputum	BAL	0.0998363	3	1	n.s.
	Bronchial		-	0.16826052		
SENSITIVITY	aspirate	BAL	0.0998363	9		n.s.
			0.0026926	0.01386013	0.1386013	
SPECIFICITY	All specimens	Sputum	5	2	2	n.s.
	All specimens		0.0012060	0.59219501		
SPECIFICITY		Induced sputum	7	3	1	n.s.
	All specimens	Bronchial	-	0.15068156		
SPECIFICITY		aspirate	0.0014397	1		n.s.
	All specimens		-	0.04256828	0.4256828	
SPECIFICITY	_	BAL	0.0025871	2	2	n.s.
	Sputum		-	0.59517745		
SPECIFICITY		Induced sputum	0.0014866	7	1	n.s.

SPECIFICITY	Sputum	Bronchial aspirate	0.0041324	0.00143062	0.0143062	*
	Sputum	BAL	-	0.00083902	0.0083902	**
SPECIFICITY		Bronchial	0.0052797	0.17308289	2	
SPECIFICITY	Induced sputum	aspirate	0.0026458	7 0.05332469	1 0.5332469	n.s.
SPECIFICITY	Induced sputum Bronchial	BAL	0.0037931	3 0.40835291		n.s.
SPECIFICITY PREVALENC	aspirate	BAL	0.0011473	9 1.84099E-	1	n.s.
E	All specimens	Sputum	0.0269285	25	1.841E-24	***
PREVALENC E	All specimens	Induced sputum	0.0068638	0.11419982	1	n.s.
PREVALENC E	All specimens	Bronchial aspirate	0.0195677	3.18425E- 19	3.1843E- 18	***
PREVALENC E	All specimens	BAL	0.0160634	4.01497E- 08	4.015E-07	***
PREVALENC E	Sputum	Induced sputum	0.0200646	0.00045144	0.0045144	**
PREVALENC	Sputum	Bronchial	0.0464962	1.90752E-	1.9075E-	***
E PREVALENC	Sputum	aspirate	0.0429919	54 8.81979E-	53 8.8198E-	***
E	Opulum	BAL	6	28	27	***
PREVALENC		Bronchial	0.0004040	7.06582E-	7.0658E-	
E PREVALENC	Induced sputum	aspirate	0.0264316 0.0229272	14 9.71951E-	13 9.7195E-	***
E	Induced sputum	BAL	9	08	9.71932	***
PREVALENC	Bronchial		-	0.16613582		
E	aspirate	BAL	0.0035043	2		n.s.
NPV	All specimens	Sputum	0.0084552	3.45875E- 06	3.4587E- 05	***
141 V	All specimens	Opatam	0.0320795	6.34282E-	6.3428E-	
NPV		Induced sputum	7	24	23	***
NPV	All specimens	Bronchial aspirate	0.0070156	1.09507E- 05	0.0001095	***
	All specimens	aopiiato	-	0.00143193	0.0143193	
NPV		BAL	0.0067415	7	7	*
NPV	Sputum	Induced sputum	0.0236243	2.45115E- 08	2.4512E-	***
INFV	Sputum	Bronchial	-	1.38418E-	1.3842E-	
NPV	·	aspirate	0.0154709	13	12	***
NID) (Sputum	DAI	-	1.30343E-	1.3034E-	***
NPV		BAL Bronchial	0.0151967	08 3.82866E-	3.8287E-	***
NPV	Induced sputum	aspirate	0.0390952	33	32	***
	·			1.88248E-	1.8825E-	
NPV	Induced sputum	BAL	-0.038821	22 0.95595959	21	***
NPV	Bronchial aspirate	BAL	0.0002741 8	0.95595959	1	n.s.
	чорнию	D/ (L	-	0.03631775	0.3631775	11.0.
PPV	All specimens	Sputum	0.0580184	2	2	n.s.
PPV	All specimens	Induced equitum	0.0728462 9	0.32999978	1	no
FFV	All specimens	Induced sputum Bronchial	0.1936901	0.00017301	0.0017301	n.s.
PPV	р	aspirate	3	7		**
PPV	All specimens	BAL	0.0298817 4	0.73106541 7	1	n.s.
I I V	Sputum	DAL	0.1308647	0.04471574	0.4471574	11.3.
PPV		Induced sputum	2	2	2	n.s.
PPV 20	Sputum	Bronchial aspirate	0.2517085 6	5.44063E- 07	5.4406E- 06	***

	Sputum		0.0879001	0.15890288		
PPV		BAL	6	6	1	n.s.
		Bronchial	0.1208438	0.22480548		
PPV	Induced sputum	aspirate	4	1	1	n.s.
			-	0.78458139		
PPV	Induced sputum	BAL	0.0429646	4	1	n.s.
	Bronchial		-	0.06700905	0.6700905	
PPV	aspirate	BAL	0.1638084	1	1	n.s.

Table S2. P-values for Table 2, performance of PCR according of the type of specimen.

PCR	Sample1	Sample2	Diff_1m2	p.val	adj.p.val	sig.code
ACCURACY	All specimens	Sputum	0.00287789	0.304418176	1	n.s.
ACCURACY	All specimens	Induced sputum	0.01147752	0.019512972	0 10512072	n e
ACCURACT	All specimens	Bronchial	0.01147702	0.018012812	0.13012312	11.3.
ACCURACY		aspirate	-0.0040849	0.123765813	1	n.s.
ACCURACY	All specimens	BAL	-0.0034643	0.283404464	1	n.s.
	Sputum	Induced		0.407040400		
ACCURACY	Sputum	sputum Bronchial	0.00859963	0.167946429	1	n.s.
ACCURACY	Opulum	aspirate	-0.0069627	0.030595877	0.30595877	n.s.
ACCURACY	Sputum	BAL		0.092258909	0.92258909	n.s.
		Bronchial				
ACCURACY	Induced sputum	aspirate	-0.0155624	0.001625285	0.01625285	*
ACCURACY	Induced sputum	BAL	-0.0149418	0.007047431	0.07047431	n.s.
ACCURACY	Bronchial aspirate	BAL	0.00062059	0.975120507	1	n.s.
SENSITIVITY	All specimens	Sputum	-0.0232511	0.562771431	1	n.s.
OFNOITH /ITY	All specimens	Induced	0.45544704	0.00050000	0.0050000	
SENSITIVITY	All specimens	sputum Bronchial	0.15514784	0.033580028	0.33580028	n.s.
SENSITIVITY	All opcomicits	aspirate	-0.0387297	0.467749275	1	n.s.
SENSITIVITY	All specimens	BAL	0.03874573	0.630382277		n.s.
	Sputum	Induced				
SENSITIVITY	01	sputum	0.1783989	0.017069317	0.17069317	n.s.
SENSITIVITY	Sputum	Bronchial aspirate	-0.0154787	0.863947971	1	n.s.
SENSITIVITY	Sputum	BAL		0.402691103		n.s.
OLINOITIVITY	•	Bronchial	0.00199076	0.402091103		11.3.
SENSITIVITY	Induced sputum	aspirate	-0.1938776	0.020902399	0.20902399	n.s.
SENSITIVITY	Induced sputum	BAL	-0.1164021	0.308470102	1	n.s.
SENSITIVITY	Bronchial aspirate	BAL	0.07747543	0.343242299	1	n.s.
SPECIFICITY	All specimens	Sputum	-0.0001495	1	1	n.s.
	All specimens	Induced				
SPECIFICITY	All on a sing	sputum	-0.0001495	1	1	n.s.
SPECIFICITY	All specimens	Bronchial aspirate	-0.0001495	1	1	n.s.
SPECIFICITY	All specimens	BAL	-0.0001495	1		n.s.
	Sputum	Induced	-0.0001430	<u> </u>		11.3.
SPECIFICITY	·	sputum	0	NA	NA	
	Sputum	Bronchial	•	NIA	A I A	
SPECIFICITY	Sputum	aspirate	0	NA	NA	
SPECIFICITY	Opulum	BAL Bronchial	0	NA	NA	
SPECIFICITY	Induced sputum	aspirate	0	NA	NA	
SPECIFICITY	Induced sputum	BAL	0	NA	NA	
SPECIFICITY	Bronchial aspirate	BAL	0	NA	NA	
PREVALENC		<i>D,</i> (<u>C</u>	- U	10.	1 1 1	
E	All specimens	Sputum	-0.0242457	1.85046E-05	0.00018505	***
PREVALENC	All specimens	Induced	0.040445	0.04404744		
E PREVALENC	All specimens	sputum Bronchial	-0.012415	0.24121711	1	n.s.
E	, iii opooiiiioiio	aspirate	0.01343573	0.015178942	0.15178942	n.s.

552

PREVALENC E	All specimens	BAL	0 0229057	0.000252936	0 00252936	**
PREVALENC	Sputum	Induced				
E DDEVALENC	Courtum	sputum	0.01183074	0.372502519	1	n.s.
PREVALENC E	Sputum	Bronchial aspirate	0.03768143	1.03816E-07	1.0382E-06	***
PREVALENC	Sputum			_	_	
E DDEVALENC		BAL	0.04715139	1.47378E-09	1.4738E-08	***
PREVALENC E	Induced sputum	Bronchial aspirate	0 02585069	0.011433057	0.11433057	n.s.
PREVALENC	maacca spatam	азрнаю	0.0200000	0.011400001	0.11400001	11.5.
E	Induced sputum	BAL	0.03532066	0.000420219	0.00420219	**
PREVALENC						
E	Bronchial aspirate	BAL	0.00946997	0.157733443	1	n.s.
NPV	All specimens	Sputum	0.0355276	1.72723E-11	1.7272E-10	***
NDV /	All specimens	Induced	0.0040000	0.040004405	0.40004405	
NPV	All anasimons	sputum Bronchial	-0.0212302	0.016901135	0.16901135	n.s.
NPV	All specimens	aspirate	-0.0448089	3.59424E-23	3.5942E-22	***
NPV	All specimens	BAL	-0.0369566	1.0787E-11	1.0787E-10	***
TVI V	Sputum	Induced	-0.0000000	1.0707E-11	1.0707E-10	
NPV	- p	sputum	-0.0567578	9.29799E-07	9.298E-06	***
	Sputum	Bronchial				
NPV	•	aspirate	-0.0803365	8.28082E-41	8.2808E-40	***
NPV	Sputum	BAL	-0.0724842	1.81678E-23	1.8168E-22	***
NID) /	In the second constant	Bronchial	0.0005707	4 505705 44	4 50505 40	***
NPV	Induced sputum	aspirate	-0.0235787	4.52576E-11	4.5258E-10	
NPV	Induced sputum	BAL	-0.0157264		0.06062577	n.s.
NPV	Bronchial aspirate	BAL	0.00785225	0.00031041	0.0031041	**
PPV	All specimens	Sputum	-0.0031153	1	1	n.s.
PPV	All specimens	Induced	0.0024452	4	4	n 0
PPV	All specimens	sputum Bronchial	-0.0031153	1	1	n.s.
PPV	All specimens	aspirate	-0.0031153	1	1	n.s.
PPV	All specimens	BAL	-0.0031153	1	1	n.s.
	Sputum	Induced	0.0001100	•	•	11.0.
PPV	•	sputum	0	NA	NA	
	Sputum	Bronchial				
PPV	0	aspirate	0	NA	NA	
PPV	Sputum	BAL	0	NA	NA	
PPV	Induced enuture	Bronchial	0	NΙΛ	NA	
	Induced sputum	aspirate	0	NA		
PPV	Induced sputum	BAL	0	NA	NA	
PPV	Bronchial aspirate	BAL	0	NA	NA	

Table S3. P-values for Table 3, performance of culture according of the type of specimen.

CULTURE	Sample1	Sample2	Diff_1m2	p.val	adj.p.val	sig.cod e
ACCURACY	All specimens	Sputum	8.0593E-06	1	1	n.s.
	All specimens		0.0004283	0.7038940		
ACCURACY		Induced sputum	7	2	1	n.s.
	All specimens	Bronchial	0.0001229			
ACCURACY		aspirate	6	0.8740244	1	n.s.
	All specimens			0.3000820		
ACCURACY		BAL	-0.0004578	1	1	n.s.
	Sputum		0.0004203	0.8005180		
ACCURACY		Induced sputum	1	8	1	n.s.
A C C L ID A C V	Sputum	Bronchial	0.0001140	1	1	n .c
ACCURACY	Sputum	aspirate	0.0001149	0.2400000	1	n.s.
A C C L ID A C V	Sputum	DAL	0.0004659	0.3496985	1	n c
ACCURACY		BAL	-0.0004658	5	1	n.s.
A C C L ID A C V	L. L	Bronchial	0.0002054	0.9656915	1	n .c
ACCURACY	Induced sputum	aspirate	-0.0003054	9	1	n.s.
A CCLID A CV	1	DAL	0.0000001	0.2068947	1	
ACCURACY	Induced sputum	BAL	-0.0008861	0.2457022	1	n.s.
A CCLID A CV	Bronchial	DAL	0.0005007	0.2457923	1	
ACCURACY	aspirate	BAL	-0.0005807	2	1	n.s.
CENICITIVITY	A II	0	0.005150	0.5072520	1	
SENSITIVITY	All specimens All specimens	Sputum	-0.005159	•	1	n.s.
CENICITIVITY	All specimens	localizacial amenterna	0.0071361	0.8889537	1	n c
SENSITIVITY	All specimens	Induced sputum	0.0220002	0.0934731	_	n.s.
CENICITIVITY	All specimens	Bronchial	0.0229893	0.0934731	0.9347319	n c
SENSITIVITY	All specimens	aspirate	4	0.5762589	3	n.s.
SENSITIVITY	All specimens	DAI	-0.0124717	0.5762569	1	n.s.
SENSITIVITY	Sputum	BAL	0.0122952	0.5301970	1	11.5.
SENSITIVITY	Opatam	Induced sputum	0.0122932	0.5301570	1	n.s.
SENSITIVITY	Sputum	-	0.0281483	0.0272888	0.2728883	11.5.
SENSITIVITY	Opatam	Bronchial	0.0281483	0.0272000		n.s.
SENSITIVITI	Sputum	aspirate	8	0.9136470		11.3.
SENSITIVITY	Opulain	BAL	-0.0073126	0.5130470	1	n.s.
SENSITIVITI			0.0158531	2	1	11.3.
SENSITIVITY	Induced sputum	Bronchial aspirate	5	0.7334086	1	n.s.
SENSITIVITY		BAL	-0.0196078	0.5232443		n.s.
SENSITIVITY	Induced sputum	BAL	-0.0196078	0.5252445	1	11.5.
SENSITIVITY	Bronchial	BAL	-0.035461	0.1727312	1	n.s.
	aspirate					11.5.
SPECIFICITY	All specimens All specimens	Sputum	0	NA	NA	
SPECIFICITY	•	Induced sputum	0	NA	NA	
SPECIFICITY	All specimens	Bronchial aspirate	0	NA	NA	
SPECIFICITY	All specimens	BAL	0	NA	NA	
SPECIFICITY	Sputum		0	NA NA	NA NA	
SPECIFICITY	Sputum	Induced sputum Bronchial	0	IVA	NA	
SPECIFICITY	- Opulum	aspirate	0	NA	NA	

555

	•					
SPECIFICITY	Sputum	BAL	0	NA	NA	
CDECIFICITY	In the section	Bronchial	0	NIA	NIA	
SPECIFICITY	Induced sputum	aspirate	0	NA	NA	
SPECIFICITY	Induced sputum Bronchial	BAL	0	NA	NA	
SPECIFICITY	aspirate	BAL	0	NA	NA	
PREVALENC	aspirate	DAL	J	147 (14/ (
E	All specimens	Sputum	-0.0269968	1.3127E-25	1.3127E-24	***
PREVALENC	All specimens	opulain	0.0203300	0.0152636	0.1526368	
E	'	Induced sputum	-0.0106277	8		n.s.
PREVALENC	All specimens	Bronchial	0.0203278			11.01
E	•	aspirate	1	2.1937E-20	2.1937E-19	***
PREVALENC	All specimens	ore burners	0.0165992			
E		BAL	2	1.7986E-08	1.7986E-07	***
PREVALENC	Sputum		0.0163691	0.0050946	0.0509465	
E		Induced sputum	6	6	9	n.s.
PREVALENC	Sputum	Bronchial	0.0473246			
E		aspirate	4	3.3813E-56	3.3813E-55	***
PREVALENC	Sputum	'	0.0435960			
E		BAL	5	2.4327E-28	2.4327E-27	***
PREVALENC		Bronchial	0.0309554			
E	Induced sputum	aspirate	8	1.0264E-17	1.0264E-16	***
PREVALENC	·		0.0272268			
E	Induced sputum	BAL	9	7.7062E-10	7.7062E-09	***
PREVALENC	Bronchial			0.1395297		
E	aspirate	BAL	-0.0037286	8	1	n.s.
NPV	All specimens	Sputum	2.2288E-05	1	1	n.s.
	All specimens			0.6371934		
NPV		Induced sputum	-0.000475	4	1	n.s.
	All specimens	Bronchial	0.0001150	0.9038903		
NPV		aspirate	6	1	1	n.s.
	All specimens			0.2934213		
NPV		BAL	-0.000475	1	1	n.s.
	Sputum			0.6723950		
NPV		Induced sputum	-0.0004973	9	1	n.s.
NPV	Sputum	Bronchial	9.2775E-05	1	1	n.s.
INF V	Sputum	aspirate	3.2773E-03	0.3311067	1	11.3.
NPV	- Paraiii	BAL	-0.0004973	0.3311007	1	n.s.
74. 4		Bronchial	0.0005900	0.5676023		
NPV	Induced sputum	aspirate	4	6	1	n.s.
NPV	Induced sputum	BAL	0	NA	NA	
74. 4	Bronchial	DIAL		0.2473768	14/1	
NPV	aspirate	BAL	-0.00059	0.2473708	1	n.s.
PPV	All specimens	Sputum	0.00033	NA	NA	. 1.5.
PPV	All specimens	•	0	NA	NA NA	
r r v	All specimens	Induced sputum Bronchial	U	IVA	IVA	
PPV	opcomiono	aspirate	0	NA	NA	
PPV	All specimens	BAL	0	NA	NA	
PPV	Sputum	Induced sputum	0	NA	NA	
	Sputum	Bronchial				
PPV		aspirate	0	NA	NA	
PPV	Sputum	BAL	0	NA	NA	

PPV	Induced sputum	Bronchial aspirate	0	NA	NA	
PPV	Induced sputum	BAL	0	NA	NA	
	Bronchial					
PPV	aspirate	BAL	0	NA	NA	

Table S4. P-values for Table 4, performance of smear microscopy according of the type of specimen.

Table S4. P-values fo	r table 4, performance	e of smear micro	oscopy according	g of the type o	of specimen.	
Pairwise Comparison	ı Direct					
Exam	Sample1	Sample2	Diff_1m2	p.val	adj.p.val	sig.code
		Induced				
SENSITIVITY	Sputum	sputum	0.15384615	0.58674615	1	n.s.
		Bronchial				
SENSITIVITY	Sputum	aspirate	-0.1538462	0.64159157	1	n.s.
SENSITIVITY	Sputum	BAL	0.25	0.4496918	1	n.s.
	Induced	Bronchial				
SENSITIVITY	sputum	aspirate	0	1	1	n.s.
	Induced					
SENSITIVITY	sputum	BAL	-0.3333333	1	1	n.s.
	Bronchial					
SENSITIVITY	aspirate	BAL	0.16666667	0.10322732	0.61936393	n.s.
		Induced				
NPV	Sputum	sputum	0.00507604	0.61977665	1	n.s.
		Bronchial				
NPV	Sputum	aspirate	-0.0058305	0.68707568	1	n.s.
NPV	Sputum	BAL	0.0070922	0.48184948	1	n.s.
	Induced	Bronchial				
NPV	sputum	aspirate	0	1	1	n.s.
	Induced					
NPV	sputum	BAL	-0.0188537	1	1	n.s.
	Bronchial					
NPV	aspirate	BAL	0.0019746	0.14625681	0.87754084	n.s.

559

560 561

Table S5. P-values for Table 5, sensitivity of PCR to predict tuberculosis according to the type of specimen using a 72 72-hours pairing window in the same patient..

Table S5. P.values for table 5, sensitivity of PCR to predict tuberculosis according to the type of specimen using a 72-hours pairing window in the same patient..

PAIRWISE COMPARISON						
PCR	Sample1	Sample2	Diff_1m2	p.val	adj.p.val	sig.code
		Induced				
SENSITIVITY	Sputum	sputum	0	1	1	n.s.
		Bronchial				
SENSITIVITY	Sputum	aspirate	-0.6153846	0.00293535	0.01761212	*
SENSITIVITY	Sputum	BAL	-0.4	0.4291953	1	n.s.
	Induced	Bronchial				
SENSITIVITY	sputum	aspirate	0.14285714	1	1	n.s.
	Induced					
SENSITIVITY	sputum	BAL	0.4	0.4291953	1	n.s.
	Bronchial					
SENSITIVITY	aspirate	BAL	0.41025641	5.551E-05	0.00033306	***
		Induced				
NPV	Sputum	sputum	0	1	1	n.s.
		Bronchial				
NPV	Sputum	aspirate	-0.0473373	0.01482072	0.08892431	n.s.
NPV	Sputum	BAL	-0.0149254	0.48447295	1	n.s.
	Induced	Bronchial				
NPV	sputum	aspirate	0.03024194	1	1	n.s.
	Induced					
NPV	sputum	BAL	0.0625	0.50109265	1	n.s.
	Bronchial					
NPV	aspirate	BAL	0.01379293	0.00043168	0.00259007	**

563

564

565 566

Table S6. P.values for table 1, sensitivity of culture to predict tuberculosis according to the type of specimen using a 72-hour pairing window within the same patient.

Table S4. P.values for table 6, sensitivity of culture to predict tuberculosis according to the type of specimen using a 72 72-hours pairing window within the same patient...

PAIRWISE						
CULTURE	Sample1	Sample2	Diff_1m2	p.val	adj.p.val	sig.code
		Induced				
SENSITIVITY	Sputum	sputum	0.05714286	0.75114104	1	n.s.
		Bronchial				
SENSITIVITY	Sputum	aspirate	-0.2903226	0.01767207	0.10603241	n.s.
SENSITIVITY	Sputum	BAL	0.10526316	0.65640773	1	n.s.
		Bronchial				
SENSITIVITY	Induced sputum	aspirate	-0.1538462	0.64159157	1	n.s.
SENSITIVITY	Induced sputum	BAL	0.30769231	0.22653276	1	n.s.
	Bronchial					
SENSITIVITY	aspirate	BAL	0.33333333	1.0772E-08	6.4633E-08	***
	Induced					
NPV	sputum	0.00526184	0.77818701	1	n.s.	
	Bronchial					
NPV	aspirate	-0.0270178	0.04176735	0.25060407	n.s.	
NPV	BAL	0.00729847	0.68809585	1	n.s.	
	Bronchial					
NPV	aspirate	-0.0406619	0.71342494	1	n.s.	
NPV	BAL	0.08074534	0.39206894	1	n.s.	
NPV	BAL	0.00940163	3.2399E-07	1.944E-06	***	

E=sputum (spontaneous expectoration), Induced sputum=Induced sputum, Bronchial aspirate=bronchial aspirate, BAL=Bronchoalveolar lavage.

569

570

571 572

Table S7. Performance of in-house Taqman PCR and Xpert for the diagnostic of pulmonary tuberculosis.

Supplementary table 2. Performance of in-house Taqman PCR and Xpert for the diagnostic of pulmonary tuberculosis.

	Accuracy	Sensitivity	Specificity	Prevalence	PPV	NPV
In-house	0.991	0.799	>0.999	0.043	0.995	0.991
TaqMan	(0.988,	(0.743,	(0.999, 1)	(0.038,	(0.971,	1) (0.988,
PCR	Ò.994)	Ò.848)	5302/5303	0.049)	191/192	0.993)
	5493/5542	191/239		239/5542		5302/5350
Xpert	0.975	0.812	0.999	0.133	0.995	0.972
	(0.967,	(0.760,	(0.997, 1)	(0.118,	(0.974,	1) (0.963,
	0.981)	0.858)	1705/1706	0.148)	212/213	0.979)
	1917/1967	212/261		261/1967		1705/1754

Table S8. Kappa with 95% confidence intervals.

	Microscopy	PCR	Culture
Sputum vs Induced sputum	0.73 (0.54,0.92)	0.49 (-0.11,1)	0.78 (0.66,0.9)
Sputum vs Bronchial aspirate	0.79 (0.62,0.97)	0.54 (0.26,0.81)	0.66 (0.50,0.82)
Sputum vs BAL	0.93 (0.80,1)	0.74 (0.40,1)	0.80 (0.65,0.96)
Induced sputum vs Bronchial aspirate	-0.02 (-0.04,0.01)	0.68 (0.34,1)	0.64 (0.37,0.90)
Induced sputum vs BAL	-0.02 (-0.05,0.01)	0.72 (0.36,1)	0.27 (-0.06,0.60)
Bronchial aspirate vs BAL	0.72 (0.62,0.82)	0.69 (0.56,1)	0.75 (0.67,0.83)

Table S9. Contingency table for kappa: microscopy

	Induced sputum		
Sputum	1 0		
1	10	5	
0	2	364	
	Bronchial		
	aspira	te	
Sputum	1	0	
1	10	1	
0	4	332	
	BAL		
Sputum	1	0	

577

578

579 580 581

582 583

584 585

586

1	7	1	
0	0	278	
	Bronchial		
	aspira	te	
Induced	1	0	
sputum			
1	0	1	
0	1	54	
	BAL		
Induced	1	0	
sputum			
1	0	1	
0	1	50	
	BAL		
Bronchial	1	0	
aspirate			
1	35	18	
0	9	3502	

Table S10. Contingency table for kappa: PCR

	Induced		
0 1	sputum		
Sputum	1	0	
1	1	150	
0	129	1927	
	Bronchia	al	
	aspirate		
Sputum	1	0	
1	0	147	
0	161	1888	
	BAL		
Sputum	1	0	
1	0	149	
0	132	1923	
	Bronchial		
	aspirate		
Induced	1	0	
sputum			
1	2	77	
0	30	2144	
	BAL	•	
Induced	1	0	
sputum			
1	3	2	
0	0	30	
	BAL		
Bronchial	1	0	
aspirate			
1	21	18	
0	1141	1033	

Table S11. Contingency table for kappa: culture

	Induced		
	sputui	n	
Sputum	1	0	
1	23	7	
0	5	368	
	Bronc		
	aspira		
Sputum	1	0	
1	16	3	
0	12	318	
	BAL		
Sputum	1	0	
1	13	4	
0	2	268	
	Bronc	hial	
	aspira	te	
Induced	1	0	
sputum			
1	7	2	
0	4	43	
	BAL		
Induced	1	0	
sputum			
1	3	7	
0	3	39	
	BAL		
Bronchial	1	0	
aspirate			
1	60	36	
0	3	3471	